Form 4: Twist Bioscience COO Sells Shares for Tax Obligations

Twist Bioscience's President and COO, Patrick John Finn, sold 4,294 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Summary

• Patrick John Finn, President and COO of Twist Bioscience Corp (TWST), reported a sale of common stock.
• The transaction occurred on February 23, 2026, involving 4,294 shares.
• The shares were sold at a price of $46.7098 per share.
• The sale was mandated to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) and was not a discretionary trade.
• Following this transaction, Patrick John Finn beneficially owns 284,129 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• The reported beneficial ownership includes shares acquired under the Issuer's Employee Stock Purchase Plan, which are exempt under Rule 16b-3(d) and Rule 16b-3(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it involves an insider selling shares, the non-discretionary nature of the 'sell to cover' transaction for tax purposes means it does not signal a change in management's confidence or the company's operational outlook.

Positives

• The sale of shares by the President and COO was non-discretionary, specifically to cover tax withholding obligations on vested Restricted Stock Units, indicating it is not a signal of a lack of confidence in the company's future performance.
• The transaction was executed under a Rule 10b5-1 plan, which suggests a pre-arranged, systematic approach to managing equity compensation and tax liabilities.

Negatives

• The transaction resulted in a reduction of 4,294 shares from the direct beneficial ownership of the President and COO.

Management Comments

• The sale represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
• These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and routine practice for executives receiving equity compensation, particularly Restricted Stock Units (RSUs), to satisfy tax liabilities upon vesting. This type of transaction is generally not indicative of an executive's sentiment regarding the company's future prospects, unlike discretionary open-market sales.

Related Party Transactions

• The sale of common stock by Patrick John Finn, President and COO, is a related party transaction as it involves an executive of the company.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale is a routine, non-discretionary event for tax purposes and does not reflect a change in the executive's outlook on the company.
• Employees: The transaction highlights the company's equity incentive plans and how tax obligations are managed for vested awards.

Key Dates

Keywords

Twist Bioscience, TWST, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Executive Compensation, Biotechnology, Genomics